JP2023545017A - 肺がんの検出及び治療のための方法 - Google Patents

肺がんの検出及び治療のための方法 Download PDF

Info

Publication number
JP2023545017A
JP2023545017A JP2023520341A JP2023520341A JP2023545017A JP 2023545017 A JP2023545017 A JP 2023545017A JP 2023520341 A JP2023520341 A JP 2023520341A JP 2023520341 A JP2023520341 A JP 2023520341A JP 2023545017 A JP2023545017 A JP 2023545017A
Authority
JP
Japan
Prior art keywords
subject
level
biological sample
sftpb
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023520341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545017A5 (https=
JPWO2022072471A5 (https=
Inventor
ハナシュ サミール
オストリン エドウィン
ファン ジィディン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2023545017A publication Critical patent/JP2023545017A/ja
Publication of JP2023545017A5 publication Critical patent/JP2023545017A5/ja
Publication of JPWO2022072471A5 publication Critical patent/JPWO2022072471A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57565—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023520341A 2020-10-02 2021-09-29 肺がんの検出及び治療のための方法 Pending JP2023545017A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063086865P 2020-10-02 2020-10-02
US63/086,865 2020-10-02
US202063106187P 2020-10-27 2020-10-27
US63/106,187 2020-10-27
PCT/US2021/052611 WO2022072471A1 (en) 2020-10-02 2021-09-29 Methods for the detection and treatment of lung cancer

Publications (3)

Publication Number Publication Date
JP2023545017A true JP2023545017A (ja) 2023-10-26
JP2023545017A5 JP2023545017A5 (https=) 2024-10-07
JPWO2022072471A5 JPWO2022072471A5 (https=) 2024-10-07

Family

ID=80950972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520341A Pending JP2023545017A (ja) 2020-10-02 2021-09-29 肺がんの検出及び治療のための方法

Country Status (6)

Country Link
US (1) US20240159753A1 (https=)
EP (1) EP4222287A4 (https=)
JP (1) JP2023545017A (https=)
KR (1) KR20230080442A (https=)
CA (1) CA3163498A1 (https=)
WO (1) WO2022072471A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110291397A (zh) * 2017-02-09 2019-09-27 得克萨斯大学体系董事会 肺癌的检测和治疗方法
CA3165068A1 (en) 2020-01-30 2021-08-05 John E. Blume Lung biomarkers and methods of use thereof
US12334190B2 (en) 2021-03-31 2025-06-17 PrognomIQ, Inc. Multi-omic assessment using proteins and nucleic acids
GB2607436A (en) * 2021-03-31 2022-12-07 Prognomiq Inc Multi-omic assessment
US12387508B2 (en) 2021-09-10 2025-08-12 PrognomIQ, Inc. Direct classification of raw biomolecule measurement data
US12007397B2 (en) 2021-09-13 2024-06-11 PrognomIQ, Inc. Enhanced detection and quantitation of biomolecules
WO2024107923A1 (en) * 2022-11-17 2024-05-23 Board Of Regents, The University Of Texas System Methods for the detection and treatment of lung cancer
EP4721103A2 (en) * 2023-05-31 2026-04-08 Board of Regents, The University of Texas System Methods for the detection and treatment of lung cancer
GB202310137D0 (en) * 2023-07-03 2023-08-16 Belgian Volition Srl Method for the detection of cancer
WO2025064345A2 (en) * 2023-09-22 2025-03-27 Board Of Regents, The University Of Texas System Methods for the detection and treatment of lung cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081569A1 (ja) * 2003-03-11 2004-09-23 Trans Genic Inc. 腫瘍マーカーとしてのｎ１，ｎ１２－ジアセチルスペルミン
US20080306017A1 (en) * 2006-01-05 2008-12-11 The Ohio State University Microrna-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Lung Cancer
JP2018523139A (ja) * 2015-06-26 2018-08-16 バイオマーク キャンサー システムズ インコーポレイテッドＢｉｏｍａｒｋ Ｃａｎｃｅｒ Ｓｙｓｔｅｍｓ Ｉｎｃ． 肺癌を検出するためのバイオマーカーパネル
US20200025765A1 (en) * 2017-02-08 2020-01-23 Fundación Para La Investigación Médica Aplicada In vitro method for the diagnosis of lung cancer
JP2020510816A (ja) * 2017-02-09 2020-04-09 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 肺癌の検出および処置のための方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006632A2 (en) * 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
WO2013154998A1 (en) * 2012-04-09 2013-10-17 Duke University Serum biomarkers and pulmonary nodule size for the early detection of lung cancer
US9753037B2 (en) * 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
CN109478231A (zh) * 2016-04-01 2019-03-15 20/20基因系统股份有限公司 帮助区别良性和恶性放射线照相明显肺结节的方法和组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081569A1 (ja) * 2003-03-11 2004-09-23 Trans Genic Inc. 腫瘍マーカーとしてのｎ１，ｎ１２－ジアセチルスペルミン
US20080306017A1 (en) * 2006-01-05 2008-12-11 The Ohio State University Microrna-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Lung Cancer
JP2018523139A (ja) * 2015-06-26 2018-08-16 バイオマーク キャンサー システムズ インコーポレイテッドＢｉｏｍａｒｋ Ｃａｎｃｅｒ Ｓｙｓｔｅｍｓ Ｉｎｃ． 肺癌を検出するためのバイオマーカーパネル
US20200025765A1 (en) * 2017-02-08 2020-01-23 Fundación Para La Investigación Médica Aplicada In vitro method for the diagnosis of lung cancer
JP2020510816A (ja) * 2017-02-09 2020-04-09 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 肺癌の検出および処置のための方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VALERIO DEL VESCOVO ET AL.: "MicroRNAs as lung cancer biomarkers", WORLD JOURNAL OF CLINICAL ONCOLOGY, vol. 5, no. 4, JPN6025037612, 10 October 2014 (2014-10-10), pages 604 - 620, ISSN: 0005807681 *

Also Published As

Publication number Publication date
WO2022072471A1 (en) 2022-04-07
CA3163498A1 (en) 2022-04-07
EP4222287A4 (en) 2024-12-18
US20240159753A1 (en) 2024-05-16
EP4222287A1 (en) 2023-08-09
KR20230080442A (ko) 2023-06-07

Similar Documents

Publication Publication Date Title
US20240159753A1 (en) Methods for the detection and treatment of lung cancer
US20230393150A1 (en) Methods and algorithms for aiding in the detection of cancer
JP7311417B2 (ja) 肺癌の検出および処置のための方法
US20230304993A1 (en) Circulating tumor cell diagnostics for lung cancer
JP6082026B2 (ja) 肺癌診断用の組成物、方法及びキット
US11193935B2 (en) Compositions, methods and kits for diagnosis of lung cancer
WO2016094330A2 (en) Methods and machine learning systems for predicting the liklihood or risk of having cancer
JP2011523049A (ja) 頭頚部癌の同定、モニタリングおよび治療のためのバイオマーカー
Li et al. Five tumor-associated autoantibodies expression levels in serum predict lung cancer and associate with poor outcome
WO2024107923A1 (en) Methods for the detection and treatment of lung cancer
CN108369233B (zh) 基于标志物人附睾蛋白4 (he4)检测肺腺癌的复发的方法及相关用途
Bogdanski et al. Protein N-Glycosylation Traits Combined With CA19-9 Accurately Distinguish Pancreatic Cancer Cases From Healthy Controls and Benign Pancreatic Diseases
CN116529603A (zh) 用于检测和治疗肺癌的方法
HK40105704A (zh) 肺癌的检测和治疗方法
EP2963124B1 (en) Biomarker combinations for use in pancreatic cancer screening
HK1227103B (zh) 用於肺癌诊断的组合物、方法和试剂盒
HK1227103A1 (en) Compositions, methods and kits for diagnosis of lung cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240927

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260303